Regulatory Update

San Francisco – – October 08, 2026 -- The U.S. Environmental Protection Agency has awarded $13.9 million to the San Francisco Estuary Partnership and the Association of Bay Area Governments to restore 1,500 acres of tidal wetland at Strip Marsh East along the State Route 37 corridor in Solano County, with construction slated to begin in 2028.

Flood cycles have destroyed 800 acres of marsh since 2000

Strip Marsh East, located within the San Pablo Bay National Wildlife Refuge, has lost 800 acres of emergent marsh since 2000 due to poor drainage that causes months-long ponding, evaporation, and hypersaline soils lethal to wetland plants. The degradation has stripped habitat from endangered species along a stretch of Highway 37 already prone to flooding.

Suzhou – October 08, 2026 -- Suzhou Ribo Life Science (06938.HK) and its Swedish subsidiary Ribocure Pharmaceuticals AB have submitted a Phase I Clinical Trial Application in the European Union for RBD3133, a small interfering RNA (siRNA) therapeutic targeting the INHBE gene for overweight and obesity.

RBD3133 silences a gene linked to healthier fat distribution in human genetic studies

RBD3133 is designed to selectively suppress INHBE, which encodes the protein activin E. Human genetic data show that individuals with naturally occurring loss-of-function variants in INHBE exhibit healthier fat distribution, improved metabolic profiles, and a lower estimated risk of coronary heart disease and type 2 diabetes.

Torrington, Conn. – October 08, 2026 -- Therap Services hosted a virtual event, "Program Integrity for States and Providers: How to Identify and Avoid Fraud, Waste, and Abuse," drawing more than 1,000 registrants including state directors, agency administrators and CEOs across the IDD, HCBS and LTSS sectors.

Virtual Event Draws Over 1,000 Registrants Amid Rising Medicaid Scrutiny

The session addressed evolving Medicaid compliance requirements and strategies to identify and avoid fraud, waste, and abuse (FWA). Presenters covered the changing Medicaid and HCBS regulatory landscape, state enforcement trends, the 2027 Medicaid Employment Mandate, and provider enrollment moratoriums.

Las Vegas – October 08, 2026 -- Frax has become the first crypto company to have an ICANN top-level domain application revealed, with .frax published under the 2026 New Generic Top-Level Domains Program. If delegated, .frax would function as a globally recognized internet domain alongside .com and .org.

.frax Would Link Blockchain-Based Naming With the Global DNS

Frax intends .frax to be the first end-to-end top-level domain connecting the traditional internet with onchain infrastructure. Users would register and manage .frax domains through Frax Name Service (FNS) on Frax's blockchain network, Fraxtal, while those domains continue to resolve through the standard global Domain Name System.

Mesa, Ariz. – October 08, 2026 -- Bright Path, a U.S. pharmaceutical manufacturer, has been named a 2026 AZBio Fast Lane Award honoree by the Arizona Bioindustry Association, recognizing milestones reached over the past 18 months including a first-of-its-kind FDA manufacturing designation and committed commercial production of hospital medicines facing chronic shortages. The company was honored at the 23rd Annual AZBio Awards at the Phoenix Convention Center during Arizona Bioscience Week.

CHARLOTTE, N.C. – October 08, 2026 -- Duke Energy has reached a settlement with North Carolina regulators and major tech firms that forces data centers and other large-load customers to pay upfront for all grid connection costs, shielding existing ratepayers from the expense of the state's data center boom.

Settlement expands cost protections to a wider pool of large-load customers

The agreement, filed with North Carolina Public Staff, lowers the threshold for mandatory customer protections from 100 megawatts to 50 megawatts with an 80% load factor. It applies to any electric service agreement signed after October 08, 2026, at Duke Energy Carolinas and Duke Energy Progress, the utility's two North Carolina subsidiaries.

Johns Creek, Ga. – October 08, 2026 -- Boehringer Ingelheim has secured U.S. Food and Drug Administration approval for a new Quarterable Snap-Tab design of PREVICOX (firocoxib) Chewable Tablets, enabling veterinarians to prescribe the canine pain medication to dogs as small as seven pounds.

Double-scored tablets expand dosing precision for veterinarians

The redesigned 57 mg and 227 mg tablets feature double scoring that allows division into quarters, giving veterinarians more granular, weight-based dosing options for dogs across a broader size range. PREVICOX is a COX-2 selective NSAID approved for controlling pain and inflammation from osteoarthritis and for postoperative pain following soft-tissue and orthopedic surgery in dogs.

Pasadena, Calif. – October 07, 2026 -- Virtualitics has become the first AI-native readiness platform to secure Impact Level 6 (IL6) Authority to Operate, clearing it to process classified workloads on Secret-level Department of War networks.

Virtualitics secured IL6 authorization in nine months, beating the typical 12-to-18-month timeline

The company achieved the certification alongside Impact Level 5 (IL5) authorization, which covers Controlled Unclassified Information and National Security Systems workloads at the unclassified level. Together the two authorizations let Department of War leaders deploy Virtualitics' AI Readiness Applications across both unclassified and Secret-level environments while meeting each tier's security requirements.

Grants, New Mexico – October 07, 2026 -- The Cibola County Board of Commissioners has passed a resolution recognizing the strategic importance of the Grants Mineral Belt and In-Situ Recovery (ISR) technology for uranium extraction, the Clean Energy Association of New Mexico (CLEAN) announced.

Cibola County formally endorses ISR as a path for uranium development

The county resolution acknowledges ISR's potential to extract naturally occurring uranium without generating tailings or requiring underground workings, according to CLEAN. CLEAN President Janet Lee-Sheriff said the vote reflects research by county officials and staff aimed at making an informed decision based on sound information.

Burlingame, Calif. – October 07, 2026 -- Enliven Therapeutics, Inc. (Nasdaq: ELVN) has reached alignment with the U.S. Food and Drug Administration on the final design of ENABLE-2, a pivotal Phase 3 trial testing relcobatinib against standard second-generation therapies in previously treated chronic myeloid leukemia (CML). The company remains on track to initiate the trial before year-end 2026.

FDA clears path for 450-patient head-to-head comparison

ENABLE-2 is designed to enroll approximately 450 adults with CML who have already received one or more tyrosine kinase inhibitors (TKIs). Participants will be randomized 1:1 to receive either relcobatinib at 80 mg once daily or an investigator-selected second-generation TKI -- dasatinib, nilotinib, or bosutinib. The primary endpoint is major molecular response (MMR) at Week 24, with MMR at Week 96 as a key secondary measure.